BioXcel Therapeutics (BTAI) EBT Margin (2022 - 2026)
BioXcel Therapeutics' (BTAI) quarterly EBT Margin came in at 6898.06% in Q1 2026, up 132397.0% year-on-year from N/an in Q1 2025, and down 23.0% quarter-over-quarter from 5608.2% in Q4 2025.
BioXcel Therapeutics (BTAI) EBT Margin (2022 - 2026) Analysis & Trends
BioXcel Therapeutics' EBT Margin history runs 5 years deep, the most recent figure standing at 6898.06% for Q1 2026.
- On a quarterly basis, EBT Margin rose 132397.0% year-over-year to 6898.06% in Q1 2026; TTM through Mar 2026 was 9755.15%, a 652372.0% decrease from a year earlier, with the FY2025 full-year figure at 10339.41%, up 99298.0% from the prior year.
- EBT Margin slipped to 6898.06% in Q1 2026 per BTAI's latest filing, from 5608.2% in the prior quarter.
- Across five years, EBT Margin topped out at 1841.03% in Q2 2024 and bottomed at 71336.55% in Q4 2022.
- The 5-year median for EBT Margin is 8629.44% (2024), against an average of 17536.64%.
- Across the five-year window, EBT Margin soared 6547033 bps in 2023 and tumbled 1469563 bps in 2025, its largest moves.
- Year by year, EBT Margin stood at 71336.55% in 2022, then jumped by 92 bps to 5866.22% in 2023, then soared by 66 bps to 1978.42% in 2024, then slumped by 183 bps to 5608.2% in 2025, then slipped by 23 bps to 6898.06% in 2026.
- Per Business Quant, the three latest BTAI EBT Margin figures stand at 6898.06% (Q1 2026), 5608.2% (Q4 2025), and 18289.8% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 10.97% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 33.51% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -41.57% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 40.73% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -7.05% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 30.30% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.35% |
| 10 | BioXcel Therapeutics | 10.62 Mn | 10.62 Mn | -77,000.00 | -6,898.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6,898.06% |
| Dec 31, 2025 | -5,608.20% |
| Sep 30, 2025 | -18,289.80% |
| Jun 30, 2025 | -16,536.67% |
| Mar 31, 2025 | -8,222.02% |
| Dec 31, 2024 | -1,978.42% |
| Sep 30, 2024 | -8,629.44% |
| Jun 30, 2024 | -1,841.03% |
| Mar 31, 2024 | -4,608.76% |
| Dec 31, 2023 | -5,866.22% |
| Sep 30, 2023 | -15,996.77% |
| Jun 30, 2023 | -13,130.85% |
| Mar 31, 2023 | -41,384.95% |
| Dec 31, 2022 | -71,336.55% |
| Sep 30, 2022 | -42,721.90% |